“We are delighted that the PERFORM trial has successfully dosed its first patient in the U.S. CD24 is a target with great potential in regulating macrophage activities in tumor environment. Supported by the striking preclinical efficacy demonstrated ...
The in vitro and in vivo anti-tumor activity of ATG-031 was evaluated in preclinical models. Methods The affinity of ATG-031 was measured using Surface Plasmon Resonance (SPR). Cell-based binding to HEK293, HEK293-CD24, human red blood cell (hRBC) and a panel of tumor cells was ...
Here, we present the ATG-031 preclinical results, including the pharmacology, pharmacodynamics (PD), pharmacokinetics (PK), and safety profiles. Methods The expression profile of CD24 was evaluated using IHC on a tissue microarray. ATG-031 underwent in vitro pharmacology assessments including but ...